COMMUNIQUÉS West-GlobeNewswire

Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
01/06/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help [...]
IBA – ACQUISITION D’ACTIONS PROPRES
01/06/2026
Louvain-la-Neuve, Belgique, 1 er juin 2026 – 21h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
IBA – ACQUISITION OF OWN SHARES
01/06/2026
Louvain-la-Neuve, Belgium, June 1 st , 2026 – 9 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
01/06/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
Fourfront Contributor launches ‘Return on Response’ campaign to highlight value of behavioral health and law enforcement crisis response partnerships
01/06/2026
Coalition warns proposed federal legislation may force more individuals to seek crisis care, reinforcing the need for community behavioral health co-response models that save time, money and lives EVERETT, SEATTLE, [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 22 - 2026
01/06/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 25 mai au 29 mai 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2026
01/06/2026
Aggregated presentation by day and by market Purchases of own shares from May 25th to May 29th 2026 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
EssilorLuxottica: Result of the payment of dividends in shares and record of the corresponding capital increase
01/06/2026
Result of the payment of dividends in shares and record of the corresponding capital increase Paris, France (June 1, 2026) – The Annual General Meeting of EssilorLuxottica has decided to grant to the shareholders the [...]
J-Star Holding Provides Additional Details on Baytown Economic Development Foundation LOI Supporting Proposed U.S. Solid-State Battery Manufacturing Facility
01/06/2026
Formal LOI Details Site Selection Support, Infrastructure Requirements, 18-Month Site Availability Commitment, and Framework for Long-Term Facility Development TAICHUNG CITY, Taiwan, June 01, 2026 (GLOBE NEWSWIRE) -- J- [...]
Thought Leadership & Innovation Foundation Releases Whitepaper on CMS Medicare Advantage Final Rule and Announces Pilot Launch of Limb Outcomes Voice (LOV)
01/06/2026
New initiatives connect outcomes data, patient voice, and the future of value-based care in orthotics and prosthetics MCLEAN, Va., June 01, 2026 (GLOBE NEWSWIRE) -- To kick off a month-long celebration of the 15-year [...]
EssilorLuxottica: Résultat du paiement du dividende en actions et constatation de l’augmentation de capital correspondante
01/06/2026
Résultat du paiement du dividende en actions et constatation de l’augmentation de capital correspondante Paris, France (1 er juin 2026) – L’Assemblée générale annuelle d’EssilorLuxottica a décidé de donner aux [...]
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
01/06/2026
LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78 [...]
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
01/06/2026
Company announcement No. 20 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL [...]
Origin Medical Announces Leadership Transition and Expands Executive Team Ahead of Commercial Launch
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Origin Medical, a pioneer in AI-powered ultrasound workflow solutions that improve access and support clinicians in delivering prenatal care, today announced a [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
01/06/2026
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE’s Strategic Expansion into AI Energy Infrastructure BOCA RATON, [...]
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
01/06/2026
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM [...]
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
01/06/2026
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive [...]
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
01/06/2026
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, [...]

Pages